



BIBCOL

Bharat Immunologicals & Biologicals Corporation Limited

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: VIII. Chola, Bulandshahr(UP)-Pin 203203

Phone 9458096110, Tele Fax -05732 238757

Email – sklalacs@yahoo.co.in Website- www.bibcol.com

No.BIB/CS/SE/LR-Q2/2021-22

Dated: 15.11.2021

To
The Listing Agreement
Bombay Stock Exchange
Phiroze Jeejeebhoy Towers,
25, Dalal Street,
Mumbai – 400 001.


Ref: Submission of Limited Review Report of the Quarterly Unaudited financial Results for the quarter ended September 2021 under Regulation 33(3)(C) of LODR

Madam/Sir,

In pursuance of Regulation 33(3) (C) of the LODR with Stock Exchange, please find enclosed the Limited Review Report along with the financial results for the Quarter ended 30th September 2021.

It is requested to kindly take the above on record please.

Thanking you,


15/11/21
(Sandip Kumar Lal)
Company Secretary





Limited Review Report

In case of M/s Bharat Immunologicals and Biologicals Corporation Limited

Date: -23-10-2021

Review Report to the Shareholders of M/s Bharat Immunologicals and Biologicals Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s Bharat Immunologicals and Biologicals Corporation Limited** for the period ended 30th September 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement

Sanjana & Associates
Chartered Accountant
FRN: 037966N



UDIN: 21559855AAAAAE5646
Date:-23-10-2021
Place:- Delhi

Sanjana Garg
Partner
M No 559855

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED

Part I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30-09-2021 Selected Information for the Period Ended 30-09-2021

(INR in Lakh)

S. No	Particulars	3 Months Ended on 30-09-2021	Preceding 3 Months Ended on 30-06-2021	Corresponding 3 Months Ended in the previous year 30-09-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME				
	a) Income from Operations	2,470.16	1,421.54	2,535.83	8,533.36
	b) Other Income	21.73	24.93	13.75	983.19
	Total Revenue (1)	2,491.89	1,446.47	2,549.58	9,516.55
2	EXPENDITURE				
	a) Cost of Material Consumed	1,420.29	2,063.81	1,981.51	6,105.99
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	775.60	-1,178.68	343.38	2,014.53
	d) Employees Benefits	305.44	283.34	346.93	1,575.25
	e) Finance Cost	122.78	115.61	116.60	477.02
	f) Depreciations and Amortization Expense	5.75	5.89	5.92	23.67
	g) Other Expense	318.03	149.20	313.77	1,043.51
	Total Expense (2)	2,947.89	1,439.18	3,108.11	11,239.97
	Profit/ (Loss) before exceptional items (1-2)	-456.00	7.29	-558.53	-1,723.42
3	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	480.09	-185.35	-171.91	-415.50
	Profit/ (Loss) from continuing Operations (3-4)	-936.09	192.64	-386.62	-1,307.92
5	Other Comprehensive Income/(Loss) (Net of Taxes)				
6	Total Comprehensive Income/ (Loss) for the period (5+6)	-936.09	192.64	-386.62	-1,307.92
7	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00
8	Earning Per Share (of INR 10/- each) not annualized				
9	a) Basic	-2.17	0.45	-0.90	-3.03
	b) Diluted	-2.17	0.45	-0.90	-3.03

Note:- Refer our Note Separately

Page 28 of 35



Part II

Selected Information for the Period Ended 30-09-2021

S. No	Particulars	3 Months Ended on 30-09-2021	Preceding 3 Months Ended on 30-06-2021	Corresponding 3 Months Ended in the previous year 30-09-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	PARTICULARS OF SHAREHOLDING				
	Public shareholding				
	- Number of Shares	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding				
	a) Pledged/ Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-
	b) Non - encumbered				
	- Number of Shares	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25

B	Particulars	3 Months ended (30-09-2021)
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

S. J. P. *Dr. P.*

[Signature]




Soyang

Segment Reporting for the Period Ended 30-09-2021

(INR in Lakhs)

S. No	Particulars	3 Months Ended on 30-09-2021	Preceding 3 Months Ended on 30-06-2021	Corresponding 3 Months Ended in the previous year 30-09-2020	Previous Year Ended as on 31-03-2021
1	SEGMENT REVENUE				
	Oral Polio Vaccine	2,469.04	1,419.58	2,533.57	8,525.15
	Zinc Dispersible Tablets	-	-	0.03	0.16
	BIB Sweet Tablets	-	0.02	-	0.01
	BIBSANIT	1.12	1.94	2.23	8.04
	Less: Inter segment revenue	-	-	-	-
	Net Sales/ Income from operations	2,470.16	1,421.54	2,535.83	8,533.36
2	SEGMENT RESULTS (Profit Before Tax)				
	Oral Polio Vaccine	-455.51	-192.37	-555.49	-1,714.63
	Zinc Dispersible Tablets	-0.03	-	-2.16	-5.11
	BIB Sweet Tablets	-	-	-	-
	BIBSANIT	-0.46	-0.27	-0.88	-3.68
	Less: Unallocable expenditure net off Unallocable Income	-	-	-	-
	Total Profit before Tax	-456.00	-192.64	-558.53	-1,723.42
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)				
	Oral Polio Vaccine	12,604.12	1,980.72	4,373.51	5,138.06
	Zinc Dispersible Tablets	7.34	-225.95	-228.56	-710.39
	BIB Sweet Tablets	-	-	0.03	0.03
	BIBSANIT	78.00	19.60	-	-
	Others	39.48	36.40	-0.38	-257.61
	Total Capital employed	12,728.94	1,810.77	4,144.60	4,170.09

S. 17. 





Notes to the Results

1. The above Un-Audited results for the Quarter ended 30th September, 2021 have been review by the Audit Committee and were taken on record by the Board of Directors in their meeting held on October 29, 2021.
2. Valuation of Closing Stock has been done on the basis of Net realizable value.
3. In quarters, depreciation has been charged on the basis of Companies Act 2013.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year ended 31.03 2021.
7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As complaint corresponding figures in the previous year have been subjected to review / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS. For Table, kindly refer Corporate Announcements on www.bseindia.com.
10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary. to make it comparable.

(Sanjay Kumar Mishra)
Managing Director

Date :- 29.10.2021

S.L.P. 



Cash Flow Statement For The Period Ended 30.09.2021

(Rupees in Lacs)

Particulars	For the Period ended 30.09.2021
A Cash Flow From Operating Activities :	
Net Profit/Loss Before Extra Ord Items	(456.00)
Adjustments For:	
Depreciation Provided	5.75
Other Comprehensive Expenses	-
Interest Expenditure	122.78
Prior Period Adjustments	-
Interest Income	20.78
Operating Profit/(Loss) Before W. Capital Changes	(306.69)
Adjustment For:	
(Increase)/Decrease In Trade Receivables	(2,289.40)
(Increase)/Decrease In Inventory	468.40
(Increase)/Decrease In Other Current Assets	276.33
Increase/(Decrease) In Trade Payables	2,681.70
(Increase)/Decrease In Provision	(101.78)
(Increase)/Decrease In Finance Assets	509.71
Increase/(Decrease) In Government Grant	-
Increase/(Decrease) In Current Liabilities	(103.38)
Increase/(Decrease) In Other Financial Liability	(19.35)
Increase/(Decrease) In Other Bank Balance	98.74
Net Cash From Operating Activities	1,214.29
B Cash Flow From Investing Activities	
Purchase Of Fixed Assets	-
Sale Of Fixed Assets	-
Interest Income	(20.78)
Net Cash Used In Investing Activities	(20.78)
C Cash Flow From Financing Activities	
Increase/(Decrease) In Deferred Grant	-
Capital Work In Progress	(2,352.80)
Increase/(Decrease) In Bank Borrowings	1,467.05
Interest Expenditure	(122.78)
Net Cash Used In Financing Activities	(1,008.52)
Net Decrease/Increase In Cash And Cash Equivalents	184.98
As At	
Cash And Cash Equivalent As At The Beginning Of The Year	122.70
Cash And Cash Equivalent As At The End Of The Year	342.80



Statement of Assets and Liabilities as at 30th September, 2021

Particulars		As at 30th September, 2021	As at 31st March, 2021
A	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	8,417.71	422.84
	(b) Capital work-in-progress	3,190.00	3,190.00
	(c) Financial Assets	1,345.38	1,251.67
	(d) Other non-current assets	44.84	44.84
	(e) Non Current Tax Assets (Net)	88.12	84.54
	(f) Deferred tax assets (net)	1,714.51	2,009.25
		14,800.57	7,003.15
2	Current assets		
	(a) Inventories	2,483.47	1,349.04
	(b) Financial Assets		
	(i) Investments		
	(ii) Trade receivables	2,289.40	1.05
	(ii) Cash and cash equivalents	342.80	122.70
	(iii) Bank balances other than (ii) above	731.14	930.88
	(c) Other current assets	1,423.51	991.75
		7,270.33	3,395.42
		22,070.91	10,398.58
	TOTAL		
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	4,318.00	4,318.00
	(b) Other Equity	6,349.94	(913.89)
		10,667.94	3,404.11
2	Non-current liabilities		
	(a) Deferred Grant	-	-
	(b) Long Term Provisions	604.58	585.39
		604.58	585.39
3	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,903.31	2,729.34
	(ii) Trade payables	2,789.57	1,479.32
	(iii) Other Financial Liabilities	68.75	49.81
	(b) Deferred Grant	-	-
	(c) Short Term Provisions	460.65	441.95
	(d) Other Current liabilities	1,576.15	1,708.66
		10,798.41	6,409.06
	TOTAL	22,070.91	10,398.58

